Data presented at the American Diabetes Association (ADA) 73rd Scientific Sessions® provides insights for use of Trajenta® (linagliptin) in adults with Type 2 Diabetes (T2D) with moderate to severe renal impairment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA®
People with a body mass index of more than 30 or a BMI of 27 with at least one weight-related condition, such as hypertension or Type 2 diabetes, are eligible for a prescription.
The American Diabetes Association wants pharmaceutical companies to make available all patient-level data on their incretin products for an independent review “that could help settle the question of whether such therapies contribute to the development of pancreatic cancer” the organization said.
The use of glyburide to treat gestational diabetes has become more frequent. Tempe A et al. conducted a prospective comparative study assessing the efficacy of glyburide to insulin in the treatment of gestational diabetes.
New forms of diabetes drugs, known as GLP-1-based drugs, and promoted as “the new darlings of diabetes treatment” make the pharmaceutical industry billions. But are they associated with an increased risk of cancer and do we know everything we should about these new treatments?
They contain a man-made version of the hormone glucagon-like peptide 1 (GLP-1), which is produced by the intestines and prompts the body to release insulin – the chemical that controls blood sugar levels.
Thirteen members voted to modify the current restrictions, while another seven voted to remove them altogether. Five members voted to continue the restrictions without changes, while one voted to remove Avandia from the market.
US government health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously believed.
Three years ago the diabetes drug Avandia was all but banned from use in the United States after researchers found that thousands of people had heart problems after taking it. Today, it is a drug of last resort for people with diabetes who are so sick that a heart attack is worth the risk.
Based on his latest study, both the Food and Drug Administration and the European Medicines Agency have begun investigations that could lead to new warnings on the drugs, or even to their removal from the market.
Over the last decade or so, an array of new drugs has arrived. Drugs that promise real improvements for both type 1 and type 2 diabetes. None of them approaches a cure.
Danish pharmaceutical company Novo Nordisk announced plans to re-brand and sell its diabetes drug liraglutide (Victoza) as a weight loss drug for obese people by 2015.
The generic cholesterol-lowering drug simvastatin, previously sold under the brand name Zocor, may diminish the positive effects of exercise in overweight and obese adults
Both drugs are injectable glucagon-like peptides (amino acids) designed to be used once a week. The company is hoping to submit data from the studies to U.S. regulatory authorities this year seeking marketing approval for the new drug.
Those with diabetes know the everyday struggle to maintain blood sugar levels at that sweet spot between too high and too low. In order to test their blood glucose levels, diabetic patients have to prick their fingers often and take medication.
A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported
The oral diabetes drug metformin may slow the aging process by mimicking the effects of a calorie-restricted diet, according to a new animal study from the United Kingdom.
The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus.
While aspirin is often recommended to lower the risk of heart attack in those with diabetes, new research suggests that it may not always help, and it could do more harm than good.